Artesunate shows potent anti-tumor activity in B-cell lymphoma
Abstract Background Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate has previously been identified as a growth suppressor in some cancer types and was tested as a new...
Main Authors: | Thea Kristin Våtsveen, Marit Renée Myhre, Chloé Beate Steen, Sébastien Wälchli, Ole Christian Lingjærde, Baoyan Bai, Pierre Dillard, Theodossis A. Theodossiou, Toril Holien, Anders Sundan, Else Marit Inderberg, Erlend B. Smeland, June Helen Myklebust, Morten P. Oksvold |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-02-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-018-0561-0 |
Similar Items
-
Severe Malaria and Artesunate Treatment, Norway
by: Kristine Mørch, et al.
Published: (2008-11-01) -
NK cells specifically TCR-dressed to kill cancer cellsResearch in context
by: Nadia Mensali, et al.
Published: (2019-02-01) -
Suspected Artesunate Resistant Malaria in South India
by: Shalini Akunuri, et al.
Published: (2018-01-01) -
Electrochemical and Theoretical Studies on the Artesunate Reduction
by: Audrey B. Silva, et al.
Published: (2020-09-01) -
Nanoparticle Delivery of Artesunate Enhances the Anti-tumor Efficiency by Activating Mitochondria-Mediated Cell Apoptosis
by: Rui Liu, et al.
Published: (2017-06-01)